ArticleIJID regions2025
A retrospective review of group B streptococcus bacteraemia in Western Sydney, Australia from 2011-2023.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virulence and resistance adaptation of Streptococcus agalactiae Ib/ST261 infecting bullfrogs in Hainan, China between 2019 and 2023.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to describe the epidemiology, clinical manifestations, management, and outcomes of group B streptococcus (GBS) bacteraemia in a large cohort spanning 13 years. Methods: This retrospective study included patients aged 16 years or older with positive GBS blood cultures obtained from four metropolitan hospitals in Western Sydney, Australia, from 1 January 2011 to 31 December 2023, inclusive. The case details of these positive cultures were reviewed using electronic medical records. Results: A total of 344 patients with GBS bacteraemia were included during the 13-year study period. The median age was 65 years, and 50% of the patients were aged 65 years or older. Known risk factors were identified in 83.1% of the patients with cardiac disease, and diabetes mellitus was the most prevalent. Skin and soft tissue infections were the most common primary manifestation (32.0%). Pregnancy-related infections represented a notable proportion of the cases (16.3%). The 7- and 30-day mortality rates were 2.3% and 5.2% respectively, with a higher mortality rate of 9.3% for those aged 65 years or older. Penicillins were the most common antibiotic class used to treat GBS bacteraemia and its resultant manifestations (66.1%). Conclusions: GBS bacteraemia most commonly occurs in individuals aged ≥65 years or during pregnancy. While mortality rates are generally low, they are twice as high in those aged ≥65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.